JP2020520995A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520995A5 JP2020520995A5 JP2020514156A JP2020514156A JP2020520995A5 JP 2020520995 A5 JP2020520995 A5 JP 2020520995A5 JP 2020514156 A JP2020514156 A JP 2020514156A JP 2020514156 A JP2020514156 A JP 2020514156A JP 2020520995 A5 JP2020520995 A5 JP 2020520995A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- cycloalkyl
- hydroxyalkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 94
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 208000017520 skin disease Diseases 0.000 claims description 19
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 14
- 229940124647 MEK inhibitor Drugs 0.000 claims description 13
- 230000001404 mediated effect Effects 0.000 claims description 13
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- -1 C 2 to C 6 alkynyl Chemical group 0.000 claims description 6
- 201000004404 Neurofibroma Diseases 0.000 claims description 6
- 206010039796 Seborrhoeic keratosis Diseases 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 201000003385 seborrheic keratosis Diseases 0.000 claims description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 5
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 206010067380 Costello Syndrome Diseases 0.000 claims description 4
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 201000004931 neurofibromatosis Diseases 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims description 3
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 206010018691 Granuloma Diseases 0.000 claims description 2
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 2
- 208000001126 Keratosis Diseases 0.000 claims description 2
- 208000005101 LEOPARD Syndrome Diseases 0.000 claims description 2
- 208000003351 Melanosis Diseases 0.000 claims description 2
- 206010062901 Multiple lentigines syndrome Diseases 0.000 claims description 2
- 150000001204 N-oxides Chemical class 0.000 claims description 2
- 208000010708 Noonan syndrome with multiple lentigines Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 208000003154 papilloma Diseases 0.000 claims description 2
- 210000001732 sebaceous gland Anatomy 0.000 claims description 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 description 19
- 238000000034 method Methods 0.000 description 12
- 206010048768 Dermatosis Diseases 0.000 description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 208000004748 plexiform neurofibroma Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508997P | 2017-05-19 | 2017-05-19 | |
| US62/508,997 | 2017-05-19 | ||
| US201862663202P | 2018-04-26 | 2018-04-26 | |
| US62/663,202 | 2018-04-26 | ||
| PCT/US2018/033547 WO2018213810A1 (en) | 2017-05-19 | 2018-05-18 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020520995A JP2020520995A (ja) | 2020-07-16 |
| JP2020520995A5 true JP2020520995A5 (https=) | 2021-07-26 |
| JP7212956B2 JP7212956B2 (ja) | 2023-01-26 |
Family
ID=62620966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514156A Active JP7212956B2 (ja) | 2017-05-19 | 2018-05-18 | 皮膚障害の処置用のピロロピリジン－アニリン化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US11161845B2 (https=) |
| EP (1) | EP3624796B1 (https=) |
| JP (1) | JP7212956B2 (https=) |
| KR (1) | KR102642411B1 (https=) |
| CN (1) | CN111065393B (https=) |
| AU (1) | AU2018270295B2 (https=) |
| CA (1) | CA3063536A1 (https=) |
| DK (1) | DK3624796T3 (https=) |
| ES (1) | ES3030506T3 (https=) |
| FI (1) | FI3624796T3 (https=) |
| IL (1) | IL270752B (https=) |
| MA (1) | MA49141A (https=) |
| MX (2) | MX389965B (https=) |
| PL (1) | PL3624796T3 (https=) |
| PT (1) | PT3624796T (https=) |
| WO (1) | WO2018213810A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7237941B2 (ja) | 2017-05-19 | 2023-03-13 | エヌフレクション セラピューティクス インコーポレイテッド | 皮膚障害の処置用の融合複素環式芳香族アニリン化合物 |
| PT3624796T (pt) * | 2017-05-19 | 2025-06-02 | Nflection Therapeutics Inc | Compostos de pirrolopiridina-anilina para tratamento de distúrbios dérmicos |
| WO2020106308A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Naphthyridinone-aniline compounds for treatment of dermal disorders |
| WO2020106306A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
| EP4233834A3 (en) * | 2018-11-20 | 2023-10-25 | NFlection Therapeutics, Inc. | Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks |
| WO2020106305A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Thienyl-aniline compounds for treatment of dermal disorders |
| CA3120351A1 (en) * | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers |
| IL301496A (en) * | 2020-09-24 | 2023-05-01 | Nflection Therapeutics Inc | Treatment of cognitive dysfunction with pyrrolopyridine-aniline compounds |
| EP4281055A4 (en) * | 2021-01-21 | 2025-06-18 | NFlection Therapeutics, Inc. | CRYSTALLINE FORMS OF A PYRROLOPYRIDINANILINE COMPOUND |
| JP2024503893A (ja) * | 2021-01-21 | 2024-01-29 | エヌフレクション セラピューティクス インコーポレイテッド | ピロロピリジン－アニリン化合物を調製するための方法 |
| IL312977A (en) | 2021-11-23 | 2024-07-01 | Nflection Therapeutics Inc | Formulations of pyrrolopyridine-aniline compounds |
| WO2023096935A1 (en) * | 2021-11-23 | 2023-06-01 | Nflection Therapeutics, Inc. | Formulations of pyrrolopyridine-aniline compounds |
| CA3254428A1 (en) * | 2022-03-17 | 2023-09-21 | SpringWorks Therapeutics Inc. | TREATMENT OF PLEXIFORM NEUROFIBROMAS (NP) ASSOCIATED WITH TYPE 1 NEUROFIBROMATOSIS (NF1) IN PEDIATRIC PATIENTS WITH MIRDAMETINIB |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| AU6242096A (en) | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| PT839525E (pt) | 1996-10-31 | 2004-10-29 | Takeda Chemical Industries Ltd | Preparacao de libertacao prolongada |
| WO1998027980A2 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7674907B2 (en) | 2004-07-23 | 2010-03-09 | Amgen Inc. | Furanopyridine derivatives and methods of use |
| JP5710855B2 (ja) | 2005-02-02 | 2015-04-30 | ネクスジェニクス・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | 神経線維腫の局所治療 |
| UA95244C2 (ru) * | 2005-06-22 | 2011-07-25 | Плексикон, Инк. | Соединения и способ модулирования активности киназ, и показания для их применения |
| GB0601962D0 (en) * | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
| GB0616214D0 (en) | 2006-08-15 | 2006-09-27 | Ucb Sa | Therapeutic Agents |
| AU2007286808B2 (en) | 2006-08-21 | 2012-12-06 | Genentech, Inc. | Aza-benzofuranyl compounds and methods of use |
| ES2528797T3 (es) | 2006-08-21 | 2015-02-12 | Genentech, Inc. | Compuestos de aza-benzotiofenilo y métodos de uso |
| EP2089359A2 (en) | 2006-10-31 | 2009-08-19 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| PE20081354A1 (es) | 2006-11-30 | 2008-11-14 | Genentech Inc | Compuestos de azaindolilo como inhibidores de mek |
| US20080312307A1 (en) | 2007-05-25 | 2008-12-18 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| CA2708176A1 (en) | 2007-12-21 | 2009-07-02 | Genentech, Inc. | Azaindolizines and methods of use |
| GB0801080D0 (en) | 2008-01-21 | 2008-02-27 | Ucb Pharma Sa | Therapeutic agents |
| GB0801081D0 (en) | 2008-01-21 | 2008-02-27 | Ucb Pharma Sa | Therapeutic agents |
| EP2240494B1 (en) | 2008-01-21 | 2016-03-30 | UCB Biopharma SPRL | Thieno-pyridine derivatives as mek inhibitors |
| GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
| US8450344B2 (en) * | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| WO2012040636A2 (en) | 2010-09-24 | 2012-03-29 | The Broad Institute, Inc. | Compounds and methods for treating diseases mediated by protease activated receptors |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| WO2014179785A1 (en) | 2013-05-03 | 2014-11-06 | Inscent, Inc. | Improved honeybee repellents and uses thereof |
| CN105384754B (zh) * | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| PT3624796T (pt) | 2017-05-19 | 2025-06-02 | Nflection Therapeutics Inc | Compostos de pirrolopiridina-anilina para tratamento de distúrbios dérmicos |
-
2018
- 2018-05-18 PT PT187315932T patent/PT3624796T/pt unknown
- 2018-05-18 MX MX2019013561A patent/MX389965B/es unknown
- 2018-05-18 DK DK18731593.2T patent/DK3624796T3/da active
- 2018-05-18 JP JP2020514156A patent/JP7212956B2/ja active Active
- 2018-05-18 AU AU2018270295A patent/AU2018270295B2/en active Active
- 2018-05-18 PL PL18731593.2T patent/PL3624796T3/pl unknown
- 2018-05-18 KR KR1020197037277A patent/KR102642411B1/ko active Active
- 2018-05-18 CN CN201880048228.4A patent/CN111065393B/zh active Active
- 2018-05-18 ES ES18731593T patent/ES3030506T3/es active Active
- 2018-05-18 US US16/615,086 patent/US11161845B2/en active Active
- 2018-05-18 FI FIEP18731593.2T patent/FI3624796T3/fi active
- 2018-05-18 WO PCT/US2018/033547 patent/WO2018213810A1/en not_active Ceased
- 2018-05-18 CA CA3063536A patent/CA3063536A1/en active Pending
- 2018-05-18 MA MA049141A patent/MA49141A/fr unknown
- 2018-05-18 EP EP18731593.2A patent/EP3624796B1/en active Active
-
2019
- 2019-11-13 MX MX2022001697A patent/MX2022001697A/es unknown
- 2019-11-18 IL IL270752A patent/IL270752B/en unknown
-
2021
- 2021-08-11 US US17/399,661 patent/US12065439B2/en active Active
-
2024
- 2024-06-17 US US18/745,768 patent/US12428418B2/en active Active
-
2025
- 2025-08-28 US US19/312,825 patent/US20250388580A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520995A5 (https=) | ||
| JP2020520994A5 (https=) | ||
| KR101651448B1 (ko) | 체지방을 국소적으로 증가시키는 방법 및 조성물 | |
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| CO2018005854A2 (es) | Inhibidores de la proteína quinasa, método de preparación y uso médico de los mismos | |
| KR20120115380A (ko) | 마이봄선 기능 장애의 치료 방법 | |
| EA035649B1 (ru) | Применение агента, активирующего рецептор гамк, для получения седативного и анестезирующего лекарственного средства | |
| RU2012101947A (ru) | Способы лечения и профилактики усталости | |
| JP6453441B2 (ja) | 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤 | |
| CN103619330A (zh) | 用于治疗糖尿病的选择性雄激素受体调节剂 | |
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| JP2014515407A5 (https=) | ||
| EP3391887A1 (en) | Wound treatment agent | |
| EP2144887A1 (en) | Dosages and methods for the treatment of cancer | |
| KR20200052934A (ko) | 경피 제제 | |
| KR20160005356A (ko) | 방사선완화 약제학적 제형 | |
| JP2022511730A5 (https=) | ||
| JP2022510587A5 (https=) | ||
| EP2144886A1 (en) | Method of treating melanoma | |
| JP2018522941A (ja) | セバコイルジナルブフィンエステルの徐放のための医薬製剤 | |
| RU2018130097A (ru) | Лечение экземы кистей | |
| RU2017134553A (ru) | Хорошо растворимые в воде соли фенилалкиламина - быстродействующего блокатора кальциевых каналов, и их применение | |
| US20200030305A1 (en) | Local anesthetic-containing acidic emulsion composition | |
| RU2015111137A (ru) | Пиридиноновые соединения для применения в фотодинамической терапии | |
| KR20220002965A (ko) | 리포산 프로드러그 |